Neurocrine Biosciences Aktie

Kaufen
Verkaufen
128,95 EUR -0,40 EUR -0,31 %
134,97 USD -0,57 USD -0,42 %
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln! Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO! Bei einem anderen Broker handeln Smartphone

Marktkap. 13,2 Mrd. EUR

KGV 53,29 Div. Rendite 0,00%

WKN 900964

ISIN US64125C1099

Symbol NBIX


Neurocrine Biosciences Aktie Analyse

16.07.19 Neurocrine Biosciences Outperform Oppenheimer & Co. Inc.
21.11.18 Neurocrine Biosciences Buy Canaccord Adams
07.08.18 Neurocrine Biosciences Buy Stifel, Nicolaus & Co., Inc.
22.02.18 Neurocrine Biosciences Buy Needham & Company, LLC
02.11.17 Neurocrine Biosciences Buy H.C. Wainwright & Co.
04.08.17 Neurocrine Biosciences Outperform BMO Capital Markets
10.05.17 Neurocrine Biosciences Buy H.C. Wainwright & Co.
03.11.16 Neurocrine Biosciences Buy Deutsche Bank AG
18.10.16 Neurocrine Biosciences Buy Needham & Company, LLC
29.06.16 Neurocrine Biosciences Buy H.C. Wainwright & Co.
08.04.16 Neurocrine Biosciences Outperform BMO Capital Markets
04.03.15 Neurocrine Biosciences overweight Barclays Capital
10.02.15 Neurocrine Biosciences Buy Deutsche Bank AG
05.02.15 Neurocrine Biosciences Outperform RBC Capital Markets
09.01.15 Neurocrine Biosciences Buy Deutsche Bank AG
21.06.12 Neurocrine Biosciences buy ROTH Capital Partners, LLC
18.12.07 Neurocrine Biosciences overweight Lehman Brothers Inc.
02.08.07 Neurocrine Biosciences overweight Lehman Brothers
18.01.07 Neurocrine Biosciences overweight Lehman Brothers
08.05.06 Neurocrine Biosciences buy A.G. Edwards & Sons
11.01.06 Neurocrine Biosciences outperform Piper Jaffray
05.01.06 Neurocrine Biosciences outperform Credit Suisse First Boston
14.10.05 Neurocrine Biosciences overweight Prudential Financial
14.10.05 Neurocrine Biosciences Overweight Prudential Securities
14.10.05 Neurocrine Biosciences overweight Prudential Financial
08.09.05 Neurocrine Biosciences outperform Piper Jaffray
04.08.05 Neurocrine Biosciences outperform Piper Jaffray
25.07.05 Neurocrine Biosciences outperform Piper Jaffray
21.07.05 Neurocrine Biosciences buy UBS
20.07.05 Neurocrine Biosciences Buy UBS
18.07.05 Neurocrine Biosciences outperform Thomas Weisel Partners
18.07.05 Neurocrine Biosciences Outperform Thomas Weisel Partners
14.02.05 Neurocrine Biosciences Overweight Lehman Brothers